This Clinical Reference Group (CRG) covers specialised treatment of certain immunological and allergic conditions. In relation to immunological conditions, this includes primary immunodeficiencies, autoimmune and autoinflammatory disease where there is associated immunodeficiency, complex autoimmune and vasculitic conditions and autoinflammatory syndromes.
In relation to allergic conditions this includes severe, complex and/or rare sub-groups.
Sharon Hodgson, Lead Commissioner
Dr Siraj Misbah, Chair
Anthony Williams, Clinical Member
William Egner, Clinical Member
Magdalena Dziadzio, Clinical Member
Mark Gompels, Clinical Member
Tomaz Garcez, Clinical Member
Susana Marinho, Clinical Member
Chris Rutkowski, Clinical Member
Dinakantha Kumararatne, Affiliate Member
Shuaib Nasser, Affiliate Member
Sarah Denman, Pharmacy Lead
Giles Ratcliffe, Public Health Lead
Laura Szutowicz, Patient & Public Voice Representative
Carla Jones, Patient & Public Voice Representative
A key part of the CRG’s work is the delivery of the ‘products’ of commissioning. These are the tools used by the 10 Hub Commissioning Teams to contract services on an annual basis.
Service specifications are important in clearly defining the standards of care expected from organisations funded by NHS England to provide specialised care. The specifications have been developed by specialised clinicians, commissioners, expert patients and public health representatives to describe both core and developmental service standards. Core standards are those that all funded providers should be able to demonstrate, with developmental standards being those which may require further changes in practice over time to provide excellence in the field.
The following service specifications fall within the scope of this CRG:
- Specialised Immunology (All Ages)
- Specialised Allergy Services (All Ages)
- Cryopyrin Associated Periodic Syndrome (All Ages)
- Diagnostic Service for Amyloidosis (All Ages)
A commissioning policy is a document that defines access to a service for a particular group of patients. A NICE Technology Appraisal Guideline on the same topic will replace, or be incorporated into, a commissioning policy as appropriate. These are important documents that are developed to ensure consistency in access to treatments nationwide.
The following policies fall within the scope of this CRG:
- Anakinra and tocilizumab for adult onset stills disease
- Anakinra for autoinflammatory
- Canakinumab for treating periodic fever syndromes: TRAPS, HIDS/MKD and FMF (ages 2 years and older) (effective from April 2020)
- Treatment of Acute Attacks in Hereditary Angiodema (Adult)
- Rituximab for cytopaenia complicating primary immunodeficiency
- Plasma-derived C1-esterase inhibitor for Prophylactic treatment of hereditary angioesema (HAE) types I and II
- Allogeneic Haematopoietic Stem Cell Transplant for Primary Immunodeficiencies (all ages)